How sequence-based AI achieve whole genome screening for billions of small molecule and antibody candidates in hours

As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma, biotech, and industrial biology. Ainnocence is expanding partnerships, ...
Seeking Alpha

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most ...
FierceBiotech

Japan biotech inks research pact in effort to develop new RNA meds

Japan biotech xFOREST Therapeutics is teaming up with a drug discovery solutions provider in a research pact aiming to develop new RNA structure-targeted small molecule therapeutics, including mRNA ...
Enid News & Eagle

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Nasdaq

Structure Therapeutics Inc. Advances ACCG-2671 as Lead Oral Amylin-Based Drug Candidate with Promising Preclinical Results

Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target engagement ...
Nasdaq

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Seeking Alpha

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...